Our Partners



Abhinav Bhalaik

Partner

Corporate and M&A, Private Equity & Venture Capital,

Abhinav is a key member of the Private Equity, Mergers & Acquisitions and Securities Law practice of the Firm.

He regularly advises various private equity firms, venture and investment funds, corporate strategic investors, multinational corporations, and investment banks on a variety of complex domestic and cross-border mergers and acquisitions, growth capital and early-stage investments. Abhinav also regularly represents portfolio companies of clients with respect to general corporate counselling, transactional matters and shareholder disputes. He has worked across a broad range of sectors (such as healthcare, pharmaceuticals, manufacturing, financial services, fintech, SAAS, edtech, gaming, consumer, agritech and media) and has advised some of the largest domestic and international clients.

Abhinav was previously a partner at SAM & Co., Mumbai. He finished his B.A. LL.B. with honors in corporate law from the National Law University, Jodhpur, India. 
 

Select Professional Experience

  • Malabar Investments in its INR 100 Crore investment in boAt.
  • CRED on its USD 140 million Series F funding round led by GIC at a post money valuation of USD 6.4 billion.
  • MedGenome in its USD 50 million Series D fund raise, led by Novo Holdings.
  • Malabar Investments on its approx. USD 50 million investment in Games 24x7.
  • Berkshire Hathaway on its potential exit from Paytm as part of the approx. USD 20 billion IPO.
  • Sequoia Capital on its investment in Rebel Foods, Eruditius, Capillary, NextSCM, Bukukas, Scaler and CarDekho.
  • RTP on its various investments, including in Mesh and Rebel Foods.
  • Ind-Swift Laboratories Limited on its agreement to sell its API business for approx. USD 200 million.
  • A 91 on its investment in Indiejewel Fashions, Hector Beverages and La Renon Healthcare.
  • Quona Capital on its investment in Arya Warehousing (approx. USD 21 million).
  • L&T Financial Services on its agreement to raise funds from Apis (approx. USD 100 million).
  • Panacea Biotech Limited on its USD 130 million fund raise from the Rise Fund.
  • Brookfield on its proposed acquisition of Suzlon Energy in a potential IBC scenario.
  • Goldman Sachs on its proposed investment in Manipal for its bid for Fortis (approx. USD 1.2 billion).
  • Sumitomo on its joint venture with the Mahindra group relating to the agro chemical business.
  • Cemex on its proposed acquisition of an Indian listed company (approx. USD 1.5 billion).
  • OMERS on its investment in HDFC (overall transaction value approx. USD 1.1 billion).
  • TPG on its proposed investment in Max Financial for acquisition of IDBI Federal Life Insurance (approx. USD 800 million).
  • Diageo on its acquisition of a majority stake in USL, for an approximate consideration of USD 2.2 billion.
  • Danone on its acquisition of Wockhardt’s nutrition business (approx. USD 300 million).
  • Actis on its various investments and exits in India, including its exit from National Stock Exchange of India Limited and Paras Pharmaceuticals Limited to Reckitt Benckiser for approx. USD 726 million.

Memberships

  • Bar Council of Maharashtra & Goa.

Our Offices

Mumbai

11, 1st Floor, Free Press House
215, Nariman Point
Mumbai – 400021

+91 22 67362222

Delhi

Express Building
9 – 10 Bahadur Shah Zafar Marg
Delhi – 110002

+91 11 23701284/5/7

 

155, ESC House, 2nd floor,
Okhla Industrial Estate, Phase 3,
New Delhi – 110020

+91 11 45062522

Bengaluru

68 Nandidurga Road
Jayamahal Extension
Bengaluru – 560046

+91 80 46462300

Kolkata

Binoy Bhavan
3rd Floor, 27B Camac Street
Kolkata – 700016

+91 33 40650155/56

DISCLAIMER

The rules of the Bar Council of India do not permit advocates to solicit work or advertise in any manner. This website has been created only for informational purposes and is not intended to constitute solicitation, invitation, advertisement or inducement of any sort whatsoever from us or any of our members to solicit any work in any manner. By clicking on 'Agree' below, you acknowledge and confirm the following:

a) there has been no solicitation, invitation, advertisement or inducement of any sort whatsoever from us or any of our members to solicit any work through this website;

b) you are desirous of obtaining further information about us on your own accord and for your use;

c) no information or material provided on this website is to be construed as a legal opinion and use of this website will not create any lawyer-client relationship;

d) while reasonable care has been taken in ensuring the accuracy of the contents of the website, Argus Partners shall not be responsible for the results of any actions taken on the basis of information provided in this website or for any error or omission in the website; and

e) in cases where the user has any legal issues, the user must seek independent legal advice.